Education
About Us
Working with TipRanks
Follow Us
Incannex Healthcare Limited Sponsored ADR (IXHL)
NASDAQ:IXHL
RESEARCH TOOLSreports
IXHL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.08 - $3.55
Previous CloseN/A
Volume10.98K
Average Volume (3M)115.70M
Market Cap
$20.94M
Enterprise Value$1.66B
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$4.10M
Price to Earnings (P/E)―
Beta2.76
Next Earnings
Aug 27, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding93,695,370
10 Day Avg. Volume56,346,300
30 Day Avg. Volume115,701,730
Financial Highlights & Ratios
PEG Ratio11.40
Price to Book (P/B)-5.68K
Price to Sales (P/S)0.00
P/FCF Ratio-1.09K
Enterprise Value/Market Cap79.48
Enterprise Value/Revenue46.23K
Enterprise Value/Gross Profit69.35K
Enterprise Value/Ebitda-41.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Incannex Healthcare Limited Sponsored ADR News
PremiumCompany Announcements
Incannex Achieves Milestone in Sleep Apnea Drug Trial
PremiumCompany Announcements
Incannex Healthcare Announces Psychedelic Therapies Joint VentureOptions Prices
Currently, No data available
---
Ownership Overview
0.11% Insiders
0.04% Mutual Funds
0.34% Other Institutional Investors
99.15% Public Companies and
Individual Investors
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $0.08 and its highest was $3.55 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $20.94M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date is Aug 27, 2025 which is in 67 days.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Incannex Healthcare Limited Sponsored ADR released its earnings results on May 15, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $0.26.
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Overvalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate is -0.29.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 93,695,370 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Incannex Healthcare Limited Sponsored ADR reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went down -61.429%.
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.6%
Last 30 Days ▲ 16.6%
Last 30 Days ▲ 16.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.51%
12-Months-Change
Fundamentals
Return on Equity
-201.88%
Trailing 12-Months
Asset Growth
-6.10%
Trailing 12-Months
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited Sponsored ADR (IXHL) is a healthcare company focused on the development and commercialization of medicinal cannabinoid and psychedelic pharmaceutical products. Operating primarily within the biotechnology and pharmaceuticals sectors, Incannex leverages cutting-edge research to address various medical conditions, including chronic pain, mental health disorders, and sleep apnea. The company is dedicated to developing innovative therapies through clinical trials and collaborations with leading research institutions.